The FDA has cleared Hollis-Eden to begin a Phase I trial of Neumene for radiation sickness. The initial study will focus on which dosages are likely to be effective in humans. The drug has worked in primate studies, reducing white blood cells and platelets in blood.
- read this story from the AP for more